SHR-1701

• Description :

  SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research[1].

• Product Name Alternative :

  Retlirafusp alfa

• UNSPSC :

  12352203

• Target :

  PD-1/PD-L1; TGF-β Receptor

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation; TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/shr-1701.html

• Purity :

  99.77

• Solubility :

  10 mM in DMSO

• Smiles :

  S[R1701]

• Molecular Formula :

  HS

• Molecular Weight :

  (174.61 kDa)

• References & Citations :

  [1]Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond) . 2022 Jan;42 (1) :17-36.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [2891860-17-4]